Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis

References

• Appleton RE. West syndrome: long-term prognosis and social aspects. Brain Dev. 2001;23:688–691.
   PubMed Web of Science ®Google Scholar
• Elterman RD, Shields WD, Bittman RM, et al. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol. 2010;25:1340–1347.
   PubMed Web of Science ®Google Scholar
• Ben‐Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand. 2011;124:5–15.
   Web of Science ®Google Scholar
• Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the guideline development subcommittee of the American Academy of Neurology and the practice committee of the child neurology society. Neurology. 2012;78:1974–1980.
   PubMed Web of Science ®Google Scholar
• Weiss KL, Schroeder CE, Kastin SJ, et al. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology. 1994;44:1944–1949.
   PubMed Web of Science ®Google Scholar
• Pearl P, Molloy-Wells E, Mcclintock W, et al. MRI abnormalities associated with vigabatrin therapy: higher risk in infants? Epilepsia. 2006;47:14.
   Web of Science ®Google Scholar
• Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314:180–181.
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R, Nonparametric A. “Trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95:89–98.
   Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. Ottawa Hospital Research Institute [ Internet]. [cited 2020 June 15]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 [cited 2020 June 15];366. Available from: https://www.bmj.com/content/366/bmj.l4898
   Google Scholar
• Dracopoulos A, Widjaja E, Raybaud C, et al. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia. 2010;51:1297–1304.
   PubMed Web of Science ®Google Scholar
• Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 2009;50:195–205.
   PubMed Web of Science ®Google Scholar
• Hussain SA, Tsao J, Li M, et al. Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent. Epilepsia. 2017;58:674–682.
   PubMed Web of Science ®Google Scholar
• Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia. 2009;50:184–194.
   PubMed Web of Science ®Google Scholar
• Dragas R, Westall C, Wright T. Changes in the ERG d-wave with vigabatrin treatment in a pediatric cohort. Doc Ophthalmol. 2014;129:97–104.
   PubMed Web of Science ®Google Scholar
• Westall CA, Wright T, Cortese F, et al. Vigabatrin retinal toxicity in children with infantile spasms. Neurology. 2014;83:2262–2268.
   PubMed Web of Science ®Google Scholar
• Kjellström U, Andréasson S, Ponjavic V. Electrophysiological evaluation of retinal function in children receiving vigabatrin medication. J Pediatr Ophthalmol Strabismus. 2011;48:357–365.
   PubMed Web of Science ®Google Scholar
• Westall CA, Nobile R, Morong S, et al. Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol. 2003;107:299–309.
   PubMed Web of Science ®Google Scholar
• Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia. 2009;50:206–216.
   PubMed Web of Science ®Google Scholar
• Riikonen R, Rener-Primec Z, Carmant L, et al. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol. 2015;57:60–67.
   PubMed Web of Science ®Google Scholar
• Partikian A, Mitchell WG. Major adverse events associated with treatment of infantile spasms. J Child Neurol. 2007;22:1360–1366.
   PubMed Web of Science ®Google Scholar
• Mitchell WG, Shah NS. Vigabatrin for infantile spasms. Pediatr Neurol. 2002;27:161–164.
   PubMed Web of Science ®Google Scholar
• Durbin S, Mirabella G, Buncic JR, et al. Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy. Invest Ophthalmol Vis Sci. 2009;50:4011–4016.
   PubMed Web of Science ®Google Scholar
• Koul R, Chacko A, Ganesh A, et al. Vigabatrin associated retinal dysfunction in children with epilepsy. Arch Dis Child. 2001;85:469–473.
   PubMed Web of Science ®Google Scholar
• Dooley J, Gordon K, Dooley K. Falsely elevated urinary ethanolamine levels due to vigabatrin. J Child Neurol. 1998;13:293–294.
   PubMed Web of Science ®Google Scholar
• Pearl PL, Poduri A, Prabhu SP, et al. White matter spongiosis with vigabatrin therapy for infantile spasms. Epilepsia. 2018;59:e40–e44.
   PubMed Web of Science ®Google Scholar
• Horton M, Rafay M, Del Bigio MR. Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration. J Child Neurol. 2009;24:1543–1546.
   PubMed Web of Science ®Google Scholar
• Cocito L, Maffini M, Loeb C. MRI findings in epileptic patients on vigabatrin for more than 5 years. Seizure. 1992;1:163–165.
   PubMedGoogle Scholar
• Hammond EJ, Ballinger WE, Lu L, et al. Absence of cortical white matter changes in three patients undergoing long-term vigabatrin therapy. Epilepsy Res. 1992;12:261–265.
   PubMed Web of Science ®Google Scholar
• Chugani HT, Shewmon DA, Sankar R, et al. Infantile spasms: II. Lenticular nuclei and brain stem activation on positron emission tomography. Ann Neurol. 1992;31:212–219.
   PubMed Web of Science ®Google Scholar
• Jackson GD, Williams SR, Weller RO, et al. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res. 1994;18:57–66.
   PubMed Web of Science ®Google Scholar
• Butler WH, Ford GP, Newberne JW. A study of the effects of vigabatrin on the central nervous system and retina of sprague dawley and lister-hooded rats. Toxicol Pathol. 1987;15:143–148.
   PubMed Web of Science ®Google Scholar
• Preece NE, Houseman J, King MD, et al. Development of vigabatrin-induced lesions in the rat brain studied by magnetic resonance imaging, histology, and immunocytochemistry. Synapse. 2004;53:36–43.
   PubMed Web of Science ®Google Scholar
• Wohlrab G, Boltshauser E, Schmitt B, et al. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics. 1999;30:130–132.
   PubMed Web of Science ®Google Scholar
• Versino M, Veggiotti P. Reversibility of vigabratin-induced visual-field defect. Lancet. 1999;354:486.
   PubMed Web of Science ®Google Scholar
• Buncic JR, Westall CA, Panton CM, et al. Characteristic retinal atrophy with secondary “inverse” optic atrophy identifies vigabatrin toxicity in children. Ophthalmology. 2004;111:1935–1942.
   PubMed Web of Science ®Google Scholar
• Maguire MJ, Hemming K, Wild JM, et al. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia. 2010;51:2423–2431.
   PubMed Web of Science ®Google Scholar
• Carmant L. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Acta Neurol Scand. 2011;124:36–47.
   Web of Science ®Google Scholar
• Malmgren K, Ben‐Menachem E, Frisén L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia. 2001;42:609–615.
   PubMed Web of Science ®Google Scholar
• Wild JM, Ahn H, Baulac M, et al. Vigabatrin and epilepsy: lessons learned. Epilepsia. 2007;48:1318–1327.
   PubMed Web of Science ®Google Scholar
• Arndt CF, Salle M, Derambure PH, et al. The effect on vision of associated treatments in patients taking vigabatrin: carbamazepine versus valproate. Epilepsia. 2002;43:812–817.
   PubMed Web of Science ®Google Scholar
• Manuchehri K, Goodman S, Siviter L, et al. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol. 2000;84:499–505.
   PubMed Web of Science ®Google Scholar
• Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia. 2008;49:108–116.
   PubMed Web of Science ®Google Scholar
• SABRIL® (vigabatrin) tablets, for oral use SABRIL® (vigabatrin) powder for oral … [ Internet]. Sabril.net. [cited 2020 June 11]. Available from: https://dev.sabril.net/prescribing-sabril
   Google Scholar
• Sergott RC, Wheless JW, Smith MC, et al. Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin. Neuro-Ophthalmology. 2010;34:20–35.
   Web of Science ®Google Scholar
• McFarlane MT, Wright T, McCoy B, et al. Retinal defect in children with infantile spasms of varying etiologies: an observational study. Neurology. 2020;94:e575–e582.
   PubMed Web of Science ®Google Scholar
• Plant GT, Sergott RC. Understanding and interpreting vision safety issues with vigabatrin therapy. Acta Neurol Scand. 2011;124:57–71.
   Web of Science ®Google Scholar
• Birch DG, Hood DC, Locke KG, et al. Quantitative electroretinogram measures of phototransduction in cone and rod photoreceptors: normal aging, progression with disease, and test-retest variability. Arch Ophthalmol. 2002;120:1045–1051.
   PubMedGoogle Scholar
• Vigabatrin: the problem of monitoring for peripheral vision loss in children. American Association for Pediatric Ophthalmology and Strabismus; 2017.
   Google Scholar
• French JA, Mosier M, Walker S, et al. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin protocol 024 investigative cohort. Neurology. 1996;46:54–61.
   PubMed Web of Science ®Google Scholar
• Dean C, Mosier M, Penry K. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia. 1999;40:74–82.
   PubMed Web of Science ®Google Scholar